Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
Delayed Nyse  -  04:00 2022-11-28 pm EST
75.78 USD   -0.76%
11/28RBC Cuts Price Target on Edwards Lifesciences to $105 From $118 Amid Foreign Exchange Impact on Margins, Keeps Outperform Rating
MT
11/28Edwards Lifesciences Says Tricuspid Valve Replacement Study Showed Survival of 90.1% After One Year
MT
11/27Edwards announces one-year data on transfemoral transcatheter tricuspid valve replacement
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Transcript : Edwards Lifesciences Corporation Presents at Transcatheter cardiovoscular Therapeutics, Sep-17-2022 06:30 PM

09/17/2022 | 06:30pm EST
Here in Boston, and we appreciate you all spending time with us as well as for those of you online. We've got a great session, I think, lined up this evening. And it's really the reflection of a lot...


ę S&P Capital IQ 2022
All news about EDWARDS LIFESCIENCES CORPORATION
11/28RBC Cuts Price Target on Edwards Lifesciences to $105 From $118 Amid Foreign Exchange I..
MT
11/28Edwards Lifesciences Says Tricuspid Valve Replacement Study Showed Survival of 90.1% Af..
MT
11/27Edwards announces one-year data on transfemoral transcatheter tricuspid valve replaceme..
PR
11/27Edwards Lifesciences Corporation Announces One-Year Data on Transfemoral Transcatheter ..
CI
11/15Insider Sell: Edwards Lifesciences
MT
11/03Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $73 From $97, Maintains N..
MT
11/01Edwards Lifesciences Launches $750 Million Accelerated Share Repurchase Agreement
MT
11/01Edwards Lifesciences Corp : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/01Edwards lifesciences announces $750 million accelerated share repurchase
PR
10/31Raymond James Lowers Edwards Lifesciences' Price Target to $85 From $120, Maintains Out..
MT
More news
Analyst Recommendations on EDWARDS LIFESCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2022 5 359 M - -
Net income 2022 1 495 M - -
Net cash 2022 1 120 M - -
P/E ratio 2022 31,9x
Yield 2022 -
Capitalization 46 852 M 46 852 M -
EV / Sales 2022 8,53x
EV / Sales 2023 7,84x
Nbr of Employees 15 700
Free-Float 95,1%
Chart EDWARDS LIFESCIENCES CORPORATION
Duration : Period :
Edwards Lifesciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDWARDS LIFESCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 75,78 $
Average target price 94,87 $
Spread / Average Target 25,2%
EPS Revisions
Managers and Directors
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Todd J. Brinton Chief Scientific Officer & VP-Advanced Technology
Nicholas J. Valeriani Independent Director
Kieran Thomas Gallahue Independent Director
Sector and Competitors
1st jan.Capi. (M$)
EDWARDS LIFESCIENCES CORPORATION-41.51%46 852
THERMO FISHER SCIENTIFIC-19.07%217 219
DANAHER CORPORATION-20.62%194 395
INTUITIVE SURGICAL, INC.-26.21%93 693
BOSTON SCIENTIFIC CORPORATION3.93%63 237
SIEMENS HEALTHINEERS AG-22.64%59 953